Effect of MD1003 (High-Dose Biotin) in spinal progressive multiple sclerosis (MS-SPI): EDSS sub-scores

被引：0
|
作者：
Papeix, C. [1 ]
Lebrun-Frenay, C. [2 ]
Defer, G. [3 ]
Labauge, P. [4 ]
Ruiz, M. [5 ,6 ,7 ]
Simon, O. [7 ]
Tourbah, A. [8 ]
机构：
[1] GH Pitie Salpetriere, Dept Neurol, Paris, France
[2] Univ Cote Azur, CHU Pasteur Neurol 2, Nice, France
[3] CHU Caen, Serv Neurol, Caen, France
[4] CHU Montpellier, Dept Neurol, Montpellier, France
[5] UPMC Univ Paris 06, Sorbonne Univ, Paris, France
[6] Hop La Pitie Salpetriere, AP HP, Dept Neurol, Paris, France
[7] MedDay Pharmaceut, Paris, France
[8] Hop Maison Blanche, Dept Neurol, Reims, France
来源：
MULTIPLE SCLEROSIS JOURNAL | 2017年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EP1780
引用
收藏
页码：938 / 939
页数：2
相关论文
共 50 条
  • [1] Effect of MD1003 (High-Dose Pharmaceutical Biotin) in Spinal Progressive Multiple Sclerosis (MS-SPI): EDSS Sub-Scores
    Papeix, Caroline
    Lebrun-Frenay, Christine
    Defer, Gilles
    Laubage, Pierre
    Ruiz, Marta
    Simon, Olivier
    Sedel, Frederic
    Tourbah, Ayman
    Lasser, Robert
    Morteau, Olivier
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 34 - 34
  • [2] Effect of MD1003 (High-Dose Biotin) in spinal progressive multiple sclerosis (MS-SPI): subgroup analyses
    Laplaud, D. -A.
    Gout, O.
    Clavelou, P.
    Pelletier, J.
    Sedel, F.
    Tourbah, A.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 402 - 403
  • [3] Effect of MD1003 (High-Dose Pharmaceutical Biotin) in Spinal Progressive Multiple Sclerosis (MS-SPI): Subgroup Analyses
    Laplaud, David-Axel
    Gout, Olivier
    Clavelou, Pierre
    Pelletier, Jean
    Simon, Olivier
    Sedel, Frederic
    Tourbah, Ayman
    Lasser, Robert
    Morteau, Olivier
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 33 - 33
  • [4] MD1003 (high doses of biotin) in progressive multiple sclerosis: subgroup analyses of the MS-SPI trial
    Tourbah, A.
    Lebrun-Frenay, C.
    Edan, G.
    Clanet, M.
    Papex, C.
    Vukusic, S.
    De Sesze, J.
    Debouverie, M.
    Gout, O.
    Clavelou, P.
    Defer, G.
    Laplaud, D.
    Moreau, T.
    Labauge, P.
    Brochet, B.
    Sedel, F.
    Pelletier, J.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 785 - 785
  • [5] Pharmacokinetics and pharmacodynamics of MD1003 (high-dose biotin) in the treatment of progressive multiple sclerosis
    Saint Paul, Laure Peyro
    Debruyne, Daniele
    Bernard, Delphine
    Mock, Donald M.
    Defer, Gilles L.
    [J]. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2016, 12 (03) : 327 - 344
  • [6] MD1003 in progressive multiple sclerosis: 24-month brain MRI results of the MS-SPI trial
    Arnold, D.
    Ranjeva, J. -P.
    Pelletier, J.
    Barrilot, C.
    Jean, B.
    Galanaud, D.
    Pierot, L.
    Edan, G.
    Clavelou, P.
    Sedel, F.
    Tourbah, A.
    Berry, I.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 35 - 36
  • [7] MD1003 in Progressive Multiple Sclerosis: 24-Month Brain Volume Changes of the MS-SPI Trial
    Arnold, Douglas L.
    Ranjeva, Jean-Phillipe
    Pelletier, Jean
    Barillot, Christian
    Jean, Betty
    Galanaud, Damien
    Pierot, Laurent
    Papeix, Caroline
    Edan, Gilles
    Clavelou, Pierre
    Simon, Olivier
    Sedel, Frederic
    Tourbah, Ayman
    Berry, Isabelle
    Morteau, Olivier
    Lasser, Robert
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 70 - 71
  • [8] Annual Relapse Rates (ARR) in Patients with Spinal Progressive Multiple Sclerosis Treated with MD1003 (High-Dose Pharmaceutical Biotin)
    Morteau, Olivier
    Lasser, Robert
    Sedel, Frederic
    Brion, Guillaume
    Tourbah, Ayman
    Simon, Olivier
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 31 - 31
  • [9] Biomarkers of treatment response in patients with progressive multiple sclerosis treated with high-dose pharmaceutical-grade biotin (MD1003)
    Collongues, Nicolas
    Kuhle, Jens
    Tsagkas, Charidimos
    Lamy, Julien
    Meyer, Nicolas
    Barro, Christian
    Parmar, Katrin
    Amann, Michael
    Wuerfel, Jens
    Kappos, Ludwig
    Moreau, Thibault
    Seze, Jerome
    [J]. BRAIN AND BEHAVIOR, 2021, 11 (02):
  • [10] Results of the Phase 3 SPI2 Study of MD1003 (high dose Pharmaceutical grade Biotin) in Progressive MS
    Cree, Bruce A. C.
    Cutter, Gary
    Wolinsky, Jerry S.
    Freedman, Mark S.
    Comi, Giancarlo
    Giovannoni, Gavin
    Hartung, Hans-Peter
    Sedel, Frederic
    Lublin, Fred
    [J]. NEUROLOGY, 2020, 94 (15)
12345